RMD RESMED INC

CIK 0000943819 42 ready 8-Ks latest August 17, 2026, 4:30 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (4)

Ready 8-Ks 42

Latest filing August 17, 2026, 4:30 PM ET

Top materiality 0.85

Event mix earnings ×21 · leadership ×10 · other ×4

Sentiment 23 pos · 0 neg · 19 neu

Latest earnings reported 2026-Q3

Executive change recent →

Recent 8-K filings for RMD

Highest-materiality recent filing

ResMed Q1 FY2025 revenue $1.22B (+11% YoY); EPS $2.11; non-GAAP EPS $2.20; dividend $0.53

October 24, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 8.01 item 9.01

Revenue $1,224.5M, up 11% YoY (11% constant currency), driven by sleep device and mask demand.
GAAP diluted EPS $2.11; non-GAAP diluted EPS $2.20, up 34% YoY; operating profit up 34%.

Read filing →

August 17, 2026, 4:30 PM ET other material materiality 0.50 neutral item 4.01 item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

ResMed dismisses KPMG, appoints PwC; Carol Burt to become Lead Director

KPMG dismissed as auditor Aug 13, 2026; PwC appointed for FY2027 subject to client acceptance.
August 6, 2026, 4:05 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

ResMed Q4 revenue up 9% to $1.5B; non-GAAP EPS $2.95 (+16%); dividend raised 10%

Q4 revenue $1.464B (+9% YoY); GAAP EPS $2.64 (+2%); non-GAAP EPS $2.95 (+16%).
July 7, 2026, 5:24 PM ET M&A materiality 0.75 positive item 2.02 item 7.01 item 9.01

ResMed sells MatrixCare to Frazier Healthcare for $490M cash; sharpens focus on sleep health

All-cash deal valued at $490M, subject to closing adjustments; expected to close in Q1 FY2027.
April 30, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

ResMed Q3 revenue $1.43B (+11%); GAAP EPS $2.74, dividend $0.60

Revenue $1,431.4M (+11% reported, +8% constant currency).
April 30, 2026, 7:59 PM ET leadership materiality 0.70 neutral item 5.02 item 9.01 ◈ executive_change ×2

ResMed CFO Brett Sandercock retires; Aaron Bloomer appointed successor

Brett Sandercock retires as CFO effective May 4, 2026; remains special advisor to CEO through Dec 2027.
January 29, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

ResMed Q2 FY2026: Revenue $1.42B (+11% YoY), non-GAAP EPS $2.81, dividend $0.60

Revenue $1,422.8M, up 11% YoY (9% constant currency); gross margin expanded 320 bps to 61.8%.
November 20, 2025, 6:59 PM ET other material materiality 0.55 neutral item 5.02 item 5.07 item 9.01

Director Sulpizio not re-elected; board shrinks to 11; stockholders approve equity plan amendments

Richard Sulpizio did not seek re-election at Nov 19 annual meeting; board reduced from 12 to 11 directors.
October 30, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

ResMed Q1 FY2026 revenue +9% to $1.34B; non-GAAP EPS $2.55 (+16%); dividend $0.60

Revenue $1,335.6M (+9% YoY, +8% constant currency); diluted EPS $2.37, non-GAAP EPS $2.55 (+16%).
August 18, 2025, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 item 9.01

ResMed elects AbbVie's Nicole Mowad-Nassar to board; director Sulpizio to retire in Nov 2025

Nicole Mowad-Nassar elected to ResMed board effective Aug 15, 2025; she is SVP at AbbVie and President of Specialty & U.S. Therapeutics Operations.
August 1, 2025, 7:59 PM ET leadership materiality 0.35 neutral item 5.02

ResMed CCO of residential care software business resigns effective Aug 1, 2025

Bobby Ghoshal, chief commercial officer of ResMed's RCS business, resigns effective August 1, 2025.
July 31, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 8.01 item 9.01

ResMed Q4 revenue up 10% to $1.35B, EPS $2.58; dividend raised 13% to $0.60

Q4 revenue $1.35B (+10% YoY, +9% CC); GAAP EPS $2.58 (+30%), non-GAAP EPS $2.55 (+23%).
April 23, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

ResMed Q3 FY2025: revenue $1.29B (+8%), GAAP EPS $2.48 (+22%), non-GAAP EPS $2.37 (+11%)

Revenue of $1.29B (+8% YoY; +9% constant currency); GAAP diluted EPS $2.48 vs $2.04 (+22%).
January 30, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

ResMed reports Q2 FY2025 revenue up 10% to $1.28B; non-GAAP EPS $2.43, up 29%

Revenue $1.28B (+10% YoY); gross margin 58.6% (+300 bps) on manufacturing efficiencies.
November 21, 2024, 6:59 PM ET other materiality 0.10 neutral item 5.07

ResMed stockholders elect all 11 director nominees, ratify KPMG, approve say-on-pay at 2024 annual meeting

All 11 director nominees elected with strong support; vote tallies ranged from ~88M to ~109M in favor.
October 24, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 8.01 item 9.01

ResMed Q1 FY2025 revenue $1.22B (+11% YoY); EPS $2.11; non-GAAP EPS $2.20; dividend $0.53

Revenue $1,224.5M, up 11% YoY (11% constant currency), driven by sleep device and mask demand.
August 16, 2024, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01 ◈ executive_change

ResMed appoints Christopher DelOrefice to board of directors, effective August 15, 2024

DelOrefice is EVP and CFO of Becton Dickinson, brings 30+ years of audit, finance and strategic expertise.
August 1, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 8.01 item 9.01

ResMed Q4 revenue $1.22B (+9% YoY); EPS $1.98; dividend up 10% to $0.53

Q4 FY2024 revenue $1,223.2M (+9% YoY, +10% constant currency); gross margin 58.5% (+350 bps).
April 25, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

ResMed Q3 FY2024 revenue $1.20B, +7% YoY; GAAP EPS $2.04, non-GAAP $2.13

Revenue $1.197B up 7% YoY (7% constant currency); mask/accessories double-digit growth.
January 24, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

ResMed Q2 FY2024 revenue $1.16B (+12% YoY); non-GAAP EPS $1.88 (+13%)

Revenue $1,162.8M (+12% YoY, +11% constant currency); GAAP op profit down 2%, non-GAAP op profit up 20% to $365.5M.
November 20, 2023, 6:59 PM ET other materiality 0.20 neutral item 5.03 item 5.07 item 9.01 ◈ Shareholder Votes ×4◈ Governance Changes

ResMed amends bylaws for universal proxy rules; annual meeting results filed

Board adopted amended bylaws on Nov 17, 2023, addressing SEC universal proxy rules (Rule 14a-19) and restricting proxy card color.
November 9, 2023, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01 ◈ executive_change ×3

ResMed appoints new CPO, CMO, CRO; COO Douglas to retire Jan 1, 2024

Rob Douglas, President & COO, retires Jan 1, 2024; transitions to special advisor to CEO immediately.
October 26, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

ResMed Q1 FY2024 revenue up 16% to $1.10B; non-GAAP EPS $1.64 (+9% YoY)

Revenue $1,102.3M (+16% YoY); operating income $289.0M (+5%); non-GAAP operating profit +10%.
August 3, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases ×2

ResMed Q4 FY2023 revenue up 23% to $1.12B; EPS $1.56 GAAP, dividend raised 9% to $0.48

Revenue $1,122.1M +23% YoY; GAAP diluted EPS $1.56 (+17%), non-GAAP $1.60 (+7%).
April 27, 2023, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

ResMed Q3 FY2023 revenue +29% to $1.12B; EPS $1.58, non-GAAP $1.68

Revenue $1,116.9M, up 29% YoY (31% constant currency); diluted EPS $1.58, non-GAAP $1.68.
March 30, 2023, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01 ◈ executive_change

ResMed Announces Retirement of Chief Administrative Officer and General Counsel David Pendarvis

David Pendarvis, global general counsel and chief administrative officer, will retire effective June 30, 2023, after over 20 years at ResMed.
January 26, 2023, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 5.02 item 8.01 item 9.01 ◈ executive_change ×2◈ Earnings Releases

ResMed Q2 revenue up 16% to $1.03B, EPS $1.53; CEO Farrell appointed Board Chair

Revenue $1,033.7M (+16% YoY, +20% constant currency); GAAP EPS $1.53, non-GAAP $1.66.
November 17, 2022, 6:59 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

ResMed shareholders elect all directors, approve say-on-pay; two directors see ~11% votes against

All 10 board nominees elected; most received >95% support with few against.
October 27, 2022, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

ResMed Q1 FY23 revenue $950.3M (+5% YoY, +9% CC); GAAP EPS $1.43, non-GAAP $1.51

Revenue $950.3M, up 5% YoY (9% constant currency); Americas (ex-SaaS) revenue up 18%.
August 12, 2022, 7:59 PM ET M&A materiality 0.75 neutral item 8.01 item 1.01 item 7.01 item 9.01

ResMed to acquire MediFox-Dan for EUR 810M; closing expected by Dec 31, 2022

Base purchase price of EUR 810M fixed via locked box; enterprise value EUR 950M.
August 11, 2022, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

ResMed Q4 revenue $914.7M (+4% YoY); dividend up 5% to $0.44; acquires MEDIFOX DAN for $1B

Q4 revenue $914.7M (+4% YoY, +8% constant currency); GAAP diluted EPS $1.33.
July 1, 2022, 7:59 PM ET leadership materiality 0.45 neutral item 5.02 item 9.01 ◈ executive_change ×2

ResMed promotes Lucile Blaise to President of Sleep & Respiratory Care effective July 1

Lucile Blaise, previously VP of Sleep & Respiratory Care for Western Europe, promoted to President of global Sleep & Respiratory Care, effective July 1, 2022.
June 30, 2022, 7:59 PM ET debt materiality 0.50 neutral item 1.01 item 2.03 item 9.01

ResMed enters amended $1.5B revolver and $200M term loan, both maturing June 2027

Revolver reduced from $1.6B to $1.5B; includes uncommitted $1B increase option.
June 14, 2022, 7:59 PM ET M&A materiality 0.85 positive item 1.01 item 7.01 item 9.01

ResMed to acquire German out-of-hospital software leader MEDIFOX DAN for ~$1B

Purchase price ~US$1.0B (€950M); expected to close by Dec 31, 2022 subject to German regulatory clearances.
May 11, 2022, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01 ◈ executive_change ×2

ResMed President of Sleep and Respiratory Care Jim Hollingshead resigns; Rob Douglas named interim

Jim Hollingshead resigned effective May 5, 2022 to pursue a new opportunity.
April 28, 2022, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 8.01 item 9.01

ResMed Q3 revenue up 12% to $864.5M; non-GAAP EPS $1.32, up 2% YoY

Revenue $864.5M (+12% YoY); constant currency growth 14%.
January 27, 2022, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 8.01 item 9.01

ResMed Q2 FY2022: Revenue $894.9M (+12% YoY), GAAP EPS $1.37, non-GAAP $1.47; dividend $0.42

Revenue $894.9M, up 12% YoY (13% constant currency); operating income $248.7M, up 12%.
November 19, 2021, 6:59 PM ET other material materiality 0.15 neutral item 5.07

ResMed shareholders elect all seven director nominees, ratify auditor, approve say-on-pay at annual meeting

All seven board nominees elected; highest vote for Harjit Gill (111.4M for), lowest for Ronald Taylor (104.1M for).
October 28, 2021, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 8.01 item 9.01

ResMed reports Q1 FY2022 revenue $904M (+20% YoY), diluted EPS $1.39, non-GAAP EPS $1.51

Revenue $904.0M, up 20% YoY (19% constant currency); all segments grew double-digits.
October 7, 2021, 7:59 PM ET leadership materiality 0.45 neutral item 5.02 ◈ executive_change

ResMed provides separation terms for former SaaS president: $704K severance, consulting deal

Rajwant Sodhi resigned as president of SaaS business effective Aug 25, 2021; termination without cause.
September 13, 2021, 7:59 PM ET other materiality 0.25 neutral item 5.03 item 9.01

ResMed amends bylaws to reduce special meeting threshold from majority to 20%

Board approved seventh amended and restated bylaws effective September 10, 2021.
August 27, 2021, 7:59 PM ET leadership materiality 0.35 neutral item 5.02 ◈ executive_change ×2

ResMed promotes Bobby Ghoshal to president of SaaS business; Raj Sodhi departs

Rajwant Sodhi will cease as president – SaaS business on Aug 25, full-time employment ends Sept 1.
August 5, 2021, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 8.01 item 9.01

ResMed Q4 FY2021 revenue up 14% to $876.1M, dividend increased 8% to $0.42

Q4 revenue $876.1M (+14% YoY); non-GAAP operating profit up 7%; diluted non-GAAP EPS $1.35.

Executive changes

Appointed

Carol Burt

Lead Director

RMD · RESMED INC

Effective: 2026-11-15
Filed: August 17, 2026, 4:30 PM ET

the Board approved the appointment of Carol Burt as lead director, effective November 15, 2026.

Departed

Ronald Taylor

Director

RMD · RESMED INC

Effective: 2026-11-18
Filed: August 17, 2026, 4:30 PM ET

On August 13, 2026, Ronald Taylor, a director of Resmed, informed the Board that he will not stand for election at Resmed’s 2026 annual meeting of stockholders (the “Annual Meeting”) and intends to retire from the Board, effective at the Annual Meeting, which is expected to be held on November 18, 2026.

Appointed

Aaron Bloomer

Chief Financial Officer

RMD · RESMED INC

Effective: 2026-05-04
Filed: April 30, 2026, 7:59 PM ET

On April 30, 2026, the Company also announced it appointed Aaron Bloomer, age 40, as Chief Financial Officer, effective May 4, 2026.

Departed

Brett Sandercock

Chief Financial Officer

RMD · RESMED INC

Effective: 2026-05-04
Successor: Aaron Bloomer
Filed: April 30, 2026, 7:59 PM ET

On April 30, 2026, ResMed Inc. (the “Company”) announced that Brett Sandercock, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will retire from his role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer.

Appointed

Christopher DelOrefice

Director

RMD · RESMED INC

Effective: 2024-08-15
Filed: August 16, 2024, 7:59 PM ET

On August 15, 2024, ResMed Inc. appointed Christopher DelOrefice to serve on its board of directors, with a term expiring at ResMed’s 2024 annual meeting of stockholders on November 21, 2024

Departed

Robert Douglas

special advisor to the CEO

RMD · RESMED INC

Effective: 2024-01-01
Filed: November 9, 2023, 6:59 PM ET

On November 9, 2023, we announced that Robert Douglas, our chief operating officer and president, will transition to a role as special advisor to the CEO effective immediately and will retire, effective January 1, 2024.

Role change

Robert Douglas

special advisor to the CEO

RMD · RESMED INC

Effective: 2023-11-09
Filed: November 9, 2023, 6:59 PM ET

On November 9, 2023, we announced that Robert Douglas, our chief operating officer and president, will transition to a role as special advisor to the CEO effective immediately and will retire, effective January 1, 2024.

Role change

Lucile Blaise

senior vice president, strategy & business development

RMD · RESMED INC

Effective: 2023-11-09
Filed: November 9, 2023, 6:59 PM ET

Lucile Blaise, our former president, sleep & respiratory care, will transition to a role as senior vice president, strategy & business development, reporting to our Chief Strategy Officer.

Departed

David Pendarvis

global general counsel, chief administrative officer, and secretary

RMD · RESMED INC

Effective: 2023-06-30
Filed: March 30, 2023, 7:59 PM ET

On March 29, 2023, David Pendarvis, our global general counsel, chief administrative officer, and secretary, notified us that he intends to retire, effective June 30, 2023.

Appointed

Michael J. 'Mick' Farrell

chair of the board of directors

RMD · RESMED INC

Effective: 2023-01-25
Filed: January 26, 2023, 6:59 PM ET

On January 25, 2023, our board of directors appointed Michael J. “Mick” Farrell as chair of our board of directors.

Role change

Dr. Peter C. Farrell

chair emeritus

RMD · RESMED INC

Effective: 2023-01-25
Filed: January 26, 2023, 6:59 PM ET

In recognition of Dr. Farrell’s long and valuable service as chair, the board of directors appointed him to the new director position of chair emeritus, effective immediately.

Role change (interim)

Robert Douglas

Interim President, Sleep and Respiratory Care

RMD · RESMED INC

Effective: 2022-07-01
Successor: Lucile Blaise
Filed: July 1, 2022, 7:59 PM ET

Concurrent with Ms. Blaise’s July 1, 2022 appointment, Robert Douglas will no longer serve as our interim president, sleep and respiratory care business.

Earnings & guidance

2026-Q3 EPS reported $7.79 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event earnings

23 positive 0 negative 19 neutral

source · RMD on sec.gov